What is the Connection between Hemoglobin Levels and Quality of Life in MDS?

Thomas LeBlanc, MD, MA, of Duke Cancer Institute continues a discussion of myelodysplastic syndromes with Jamie Koprivnikar, MD, of Hackensack University Medical Center and Andrew Brunner, MD, of Massachusetts General Hospital. Subjects explored in this segment include patient reported outcomes, transfusion dependence, and time toxicity in patients being treated for lower-risk disease.